Details of Phase III trials for AstraZeneca PLC’s first biologic respiratory medicine benralizumab released at the European Respiratory Society International Congress on Sept. 5 show the monoclonal antibody directly and quickly killed inflammatory cells called eosinophils which drive inflammation and airway hyper-responsiveness in around 50% of asthma patients.
In an interview with Scrip, Tom Keith-Roach, who leads AstraZeneca’s respiratory, inflammation and autoimmune business, was optimistic about the product's...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
